Rein Therapeutics Inc. RNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.44M | 2.16M | 1.96M | 3.81M | 2.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.08M | 5.23M | 3.96M | 5.49M | 6.87M |
| Operating Income | -6.08M | -5.23M | -3.96M | -5.49M | -6.87M |
| Income Before Tax | -6.38M | -5.84M | -32.68M | -5.58M | -6.82M |
| Income Tax Expenses | -- | -- | -712.00K | -- | -- |
| Earnings from Continuing Operations | -6.38M | -5.84M | -31.97M | -5.58M | -6.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.38M | -5.84M | -31.97M | -5.58M | -6.82M |
| EBIT | -6.08M | -5.23M | -3.96M | -5.49M | -6.87M |
| EBITDA | -6.08M | -5.23M | -3.96M | -5.49M | -6.87M |
| EPS Basic | -0.07 | -0.21 | -1.09 | -0.21 | -0.28 |
| Normalized Basic EPS | -0.05 | -0.13 | -0.09 | -0.13 | -0.18 |
| EPS Diluted | -0.07 | -0.21 | -1.09 | -0.21 | -0.28 |
| Normalized Diluted EPS | -0.05 | -0.13 | -0.09 | -0.13 | -0.18 |
| Average Basic Shares Outstanding | 85.77M | 28.04M | 29.27M | 26.36M | 24.19M |
| Average Diluted Shares Outstanding | 85.77M | 28.04M | 29.27M | 26.36M | 24.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |